Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.31 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3539633 | 0.84 | ELANE (0.37) | HDAC1NLRP3ELANEMEN1GAA | |
| SCHEMBL19538513 | 0.81 | HDAC1 (0.35) | HDAC1NLRP3ELANEMEN1GAA | |
| SCHEMBL11545148 | 0.70 | — | — | |
| SCHEMBL9892944 | 0.69 | HDAC1 (0.40) | HDAC1NLRP3MEN1GAAKMT2A | |
| SCHEMBL28770366 | 0.64 | KDM4E (0.44) | MEN1GAAKMT2AMCL1L3MBTL1 | |
| SCHEMBL12999910 | 0.64 | KMT2A (0.42) | HDAC1MEN1KMT2AL3MBTL1 | |
| SCHEMBL12999920 | 0.64 | NLRP3 (0.50) | NLRP3ELANEMEN1GAAKMT2A | |
| SCHEMBL6645915 | 0.63 | HPGD (0.40) | HDAC1NLRP3MEN1GAAKMT2A | |
| SCHEMBL6361286 | 0.63 | LMNA (0.41) | GAAL3MBTL1ADORA3 | |
| SCHEMBL15290761 | 0.63 | HDAC1 (0.40) | HDAC1NLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10196423-B2 | NPR-B agonists | SHIRE ORPHAN THERAPIES GMBH (DE) | 2019-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10196423-B2 | NPR-B agonists | NPR1, NPR3, NPBWR1 | HDAC1 4170/4885NLRP3 545/4885ELANE 1747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.